Lord, Abbett & Co
FBRX

Lord, Abbett & Co’s Forte Biosciences FBRX Stock Holding History

Lord, Abbett & Co’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
210,442
+95,807
+84% +$2.27M 0.01% 490
2026
Q1 		$2.97M Buy
+114,635
New +$3.3M 0.01% 507

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Lord, Abbett & Co's FBRX Position: Q2 2026 in Review

Lord, Abbett & Co increased its Forte Biosciences (FBRX) stake by 84% in Q2 2026, buying an estimated $2.27M and bringing the position to 210,442 shares worth $4.47M. The position accounts for 0.01% of the portfolio, ranked #490.

Lord, Abbett & Co first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Lord, Abbett & Co held 210,442 shares of Forte Biosciences worth $4.47M as of Q2 2026.
  • Lord, Abbett & Co bought 95,807 Forte Biosciences shares in Q2 2026, an estimated $2.27M.
  • Forte Biosciences made up 0.01% of Lord, Abbett & Co's portfolio in Q2 2026, its #490 holding.
  • Lord, Abbett & Co first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.